Global Cancer Statistics Demonstrate the Complex Interplay Between Societal, Economic, and Lifestyle FactorsJanuary 3rd 2019
In “Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,” Freddie Bray, BSC, MSC, PhD, and colleagues describe the global magnitude and distribution of the disease overall and discuss the associated risk factors and prospects for prevention of the major cancers observed worldwide in their study.
Quantifying the Benefits of Precision OncologyDecember 14th 2018
Precision medicine has produced some dramatic successes in patients with advanced cancer. With developments in molecular profiling, targeted therapies are being applied to multiple tumors, most notably in advanced melanoma, NSCLC, and several types of leukemia. Alison Schram, MD, and David M. Hyman, MD, point out the challenges in determining the proportion of patients who will benefit from receiving targeted therapies.
Community Oncologists Say Proposed CMS Updates to E/M Services Undermine Patient CareDecember 4th 2018
A proposed 2019 rule change for services furnished under the Medicare Physician Fee Schedule is not going down well with oncologists. In July, the Centers for Medicare & Medicaid Services issued the proposed change that would lower some payments for patient evaluation and maintenance services.
Trial Investigators Discuss FDA Draft Guidance on Master ProtocolsDecember 1st 2018
Complex drug trials that use a single protocol to test either 1 agent against multiple cancers or multiple agents against 1 cancer can make drug testing faster, cheaper, and more informative, particularly when those trials use the data to constantly improve protocols.
New Radiation Therapy Guidelines for Prostate Cancer Lowers Treatment Burden and CostNovember 30th 2018
For clinicians who treat men with early-stage prostate cancer in their clinical practice, a new clinical guideline on the use of external beam radiation therapy has been developed by a panel of experts representing the American Society of Clinical Oncology, American Society for Radiation Oncology, and American Urological Association.
Antibiotics Reduce ICI Efficacy for Patients With Urological CancersNovember 30th 2018
Patients with metastatic renal and urothelial bladder cancer who receive antibiotics concomitantly with immune checkpoint inhibitors have shorter progression-free survival and overall survival rates than patients who do not, according to a poster presented at the European Congress on Immunotherapies in Cancer™ conference, hosted by Physicians’ Education Resource®, LLC, September 21 and 22, 2018, in Barcelona, Spain.
Vedolizumab Induces Remission of Immunotherapy-Related Diarrhea, ColitisNovember 29th 2018
Vedolizumab induced clinical, endoscopic, and histologic remission of steroid-refractory, immune-mediated enterocolitis in patients receiving immune checkpoint inhibitorsfor cancer treatment, according to the results of a small retrospective study presented at the 2018 American College of Gastroenterology Annual Meeting.
Greenwald Celebrates Successes in National Colorectal Cancer Screening CampaignNovember 29th 2018
The National Colorectal Cancer Roundtable may have come up short in its goal to get 80% of American adults ≥50 years screened for colorectal cancer by 2018, but David A. Greenwald, MD, told his audience at the 2018 American College of Gastroenterology Annual Meeting that the group can point to smaller victories that deserve recognition.
Study Favors Pancreatic Cancer Screening for High-Risk PatientsNovember 27th 2018
There may be pros and cons for screening people who do not have symptoms of pancreatic cancer, but the evidence clearly supports screening those at a high risk for developing the disease, Vivek Kaul, MD, told his audience at the 2018 American College of Gastroenterology Annual Meeting.
Moving the Bar in Pancreatic CancerNovember 27th 2018
Recent advancements in systemic therapies are changing the treatment landscape for patients with pancreatic cancer. New therapeutics and treatment strategies are emerging, meaning more patients than ever are candidates for curative procedures.
What Is the Role of SCT as Novel Agents Emerge for Relapsed/Refractory HL?November 19th 2018
During a presentation at the National Comprehensive Cancer Network 13th Annual Conference: Hematologic Malignancies Phillippe Armand, MD, PhD, discusses how novel agents could be used in the future either to postpone, permit, or even replace allogeneic stem cell transplantation.
Small Molecule Inhibitors Prove Effective in Targeting NHLNovember 17th 2018
A greater understanding of molecular pathogenesis in non-Hodgkin lymphoma has led to the identification of rational targets for novel small molecule inhibitors, according to Andrew D. Zelenetz, MD, PhD. Combinations of these therapies may also provide greater responses and the potential for therapy discontinuation.